Tanabe Seiyaku Granted the Rights for TA-1790 to Vivys Inc. (U.S.A.)
July 23, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Tanabe Seiyaku Granted the Rights for TA-1790 to Vivys Inc. (U.S.A.) - JCN Newswire
Share:
Tanabe Seiyaku Granted the Rights for TA-1790 to Vivys Inc. (U.S.A.)

Tokyo, Mar 6, 2001 - (JCN Newswire) - Tanabe Seiyaku Co., Ltd. (Mr. Toshio Tanaka, President and CEO) announced today that Tanabe Seiyaku has granted a right to VIVUS, Inc. (VIVUS) for TA-1790, a phosphodiesterase type 5 (PDE5) inhibitor for the treatment of sexual dysfunction currently in early clinical development. VIVUS receives an exclusive worldwide right, except for Japan and some Asian countries, to develop and market TA-1790.

Tanabe Seiyaku has started the collaborations with foreign partners to grant an exclusive right to develop and market Tanabe's own compounds such as anti-diabetic and anti- inflammatory agents for the western countries in succession since last year. Tanabe Seiyaku is accelerating the simultaneous clinical development of TA-1790 through VIVUS' expertise and advantages in the field of sexual dysfunction.

The mechanism of TA-1790 is as follows. When a man is sexually excited, the cGMP level is increased in the penis and it causes the erection. In patients with erectile dysfunction, it is known that the concentration of cGMP or the penile sensitivity to cGMP is not enough to induce the erection. PDE5 is a crucial enzyme for the breakdown of cGMP in the penis. Therefore, TA-1790 can potentiate the increase in cGMP level during sexual stimulation through the inhibition of PDE5, and to help the erection. Orally administered TA-1790 was confirmed that it is well tolerated in healthy male volunteers in a single dose Phase I study.

VIVUS is an American pharmaceutical company, which was founded in 1991, and is focusing to develop and market products in the field of sexual dysfunction. VIVUS has excellent expertise in clinical development and regulatory affairs in this fie ld. VIVUS will be responsible for the development of TA-1790 as one of its priority compounds for its territories. VIVUS holds patents relating to local and transurethral delivery systems for the treatment of sexual dysfunction that allow it to develop and commercialize products of TA-1790 using these delivery systems for the patients.

About Tanabe Seiyaku Co., Ltd.

Tanabe Seiyaku Co., Ltd. (TSE: 4508) is a manufacturer and distributor of pharmaceuticals for cardiovascular system, circulatory system, central nervous system, respiratory system and gastrointestinal system, tonics, antibiotics, chemotherapeutics, hormones, vitamins, diagnostic agents and mediums, as well as other products such as food additives and cosmetics. Operations are carried out through various divisions: prescription drugs, OTC drugs, diagnostic agents, animal drugs, chemicals, food additives, and dies/pigments.

Contact

remove  E-mail: remove

 


Mar 6, 2001
Source: Tanabe Seiyaku Co., Ltd.

Tanabe Seiyaku Co., Ltd. (TSE: 4508)

From the Japan Corporate News Network
http://www.japancorp.net
Topic: New Product
View more news from these Sectors: Health & Med, Health & Med


 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)